FAQ

LY 315920

Known as: LY-315920, LY315920, LY333013 
 

Topic mentions per year

Topic mentions per year

1996-2016
012319962016

Related topics

Related topics

1 relation

Broader (1)

varespladib methyl

Related mentions per year

Related mentions per year

1996-2016
1990200020102020
LY 315920
varespladib methyl

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation
Snakebite remains a neglected medical problem of the developing world with up to 125,000 deaths each year despite more than a… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 2
  • figure 3
Is this relevant?
2015
2015
sPLA2-IIA Augments Oxidized LDL-Induced MCP-1 Expression in Vitro Through Activation of Akt.
BACKGROUND/AIMS Group IIA secretory phospholipase A2 (sPLA2-IIA) has an important role in atherosclerosis. In this study, we… (More)
Is this relevant?
2014
2014
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells
Lung cancer is the leading cause of cancer death worldwide. There is an urgent need for early diagnostic tools and novel… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2008
2008
Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
We report a series of inhibitors of secreted phospholipases A2 (sPLA2s) based on substituted indoles, 6,7-benzoindoles, and… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2007
2007
Regioselective synthesis of 4- and 7-alkoxyindoles from 2,3-dihalophenols: application to the preparation of indole inhibitors of phospholipase A2.
An efficient and regioselective synthesis of 4- and 7-alkoxyindoles has been developed from commercially available starting… (More)
Is this relevant?
2005
2005
A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.
OBJECTIVE To evaluate the efficacy and safety of a selective inhibitor of secretory phospholipase (sPLA2), LY333013, in the… (More)
Is this relevant?
2005
2005
Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16.
PURPOSE How vitamin A contributes to the maintenance of the wet-surfaced phenotype at the ocular surface is not well understood… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2005
2005
Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma.
The possible roles of secretory phospholipases A2 (sPLA2) in asthma include the release of arachidonic acid from cellular… (More)
Is this relevant?
1999
1999
Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti…
LY315920 is a potent, selective inhibitor of recombinant human, group IIA, nonpancreatic secretory PLA2 (sPLA2). In a chromogenic… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 6
Is this relevant?
1996
1996
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
The preceding papers of this series detail the development of functionalized indole-3-acetamides as inhibitors of hnps-PLA2. We… (More)
Is this relevant?